Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Part of Type 2 Diabetes

77 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Type 2 Diabetes Mellitus

1160 trials tracked for Type 2 Diabetes Mellitus: 618 in phase 3 or 4 and 215 with published results. The most-cited published study has 15438 citations.

1,160Trials tracked
618Phase 3 & 4
0Recruiting
215With published results
Phase distribution
Phase 4 189 Phase 3 429 Phase 2 167 Phase 1 125 Other / NA 250
  1. Phase 3 Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control Completed · 15,438 cited
  2. Phase 3 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Completed · 7,545 cited
  3. Phase 3 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes Completed · 6,848 cited
  4. Phase 3 Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) Completed · 2,606 cited
  5. Phase 3 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Completed · 1,992 cited
  6. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone Completed · 1,041 cited
Show 44 more trials
  1. Phase 4 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed · 1,008 cited
  2. Phase 3 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Completed · 783 cited
  3. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes Completed · 731 cited
  4. Phase 3 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Completed · 649 cited
  5. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Completed · 591 cited
  6. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Completed · 591 cited
  7. Phase 3 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Completed · 570 cited
  8. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes Completed · 489 cited
  9. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Completed · 482 cited
  10. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Completed · 460 cited
  11. Phase 3 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes Completed · 457 cited
  12. Phase 3 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Completed · 420 cited
  13. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Completed · 408 cited
  14. Phase 3 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Completed · 408 cited
  15. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Completed · 376 cited
  16. Phase 3 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes Completed · 369 cited
  17. Phase 3 A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus Completed · 366 cited
  18. Phase 3 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed · 363 cited
  19. Phase 4 VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus Completed · 360 cited
  20. Phase 3 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes Completed · 355 cited
  21. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment Completed · 346 cited
  22. Phase 3 A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Completed · 344 cited
  23. Phase 3 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes Completed · 299 cited
  24. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed · 288 cited
  25. Phase 3 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin Completed · 288 cited
  26. Phase 3 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Completed · 278 cited
  27. Phase 3 A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus Completed · 267 cited
  28. Phase 4 SGLT2 Inhibition in Combination With Diuretics in Heart Failure Completed · 255 cited
  29. Phase 3 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) Completed · 254 cited
  30. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes Completed · 254 cited
  31. Phase 3 GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin Completed · 254 cited
  32. Phase 4 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus Completed · 252 cited
  33. Phase 3 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine Completed · 252 cited
  34. Phase 4 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy Completed · 250 cited
  35. Phase 3 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Completed · 227 cited
  36. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes Completed · 222 cited
  37. Phase 3 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy Completed · 218 cited
  38. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Completed · 218 cited
  39. Phase 3 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Completed · 213 cited
  40. Phase 4 Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist Completed · 199 cited
  41. Phase 3 A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Completed · 193 cited
  42. Phase 3 A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes Completed · 192 cited
  43. Phase 3 A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). Completed · 191 cited
  44. Phase 3 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus Completed · 189 cited

Showing the 50 most-cited and recently-updated of 1,160 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Type 2 Diabetes Mellitus: what the trials found

Semaglutide treatment was associated with significant reductions in body weight (ranging from -4.0% to -13.5%; p<0.0001) and a high proportion of participants achieving at least a 5% reduction in body weight (p<0.0001) 2. In addition, Semaglutide was associated with improvements in treatment satisfaction scores (DTSQc) and significant reductions in daily insulin doses for some patients 6.

Semaglutide did not show statistically significant changes in kidney oxygenation (Cortex or Medulla) or global kidney perfusion 3. Insulin Icodec was associated with a significant reduction in HbA1c (-1.23; p<0.0001) and recorded 13 instances of clinically significant hypoglycemia 5.

Testosterone gel was associated with measurable changes in bone strength as determined by Finite Element Analysis (p<0.05) 1.

Recent results — preliminary, needs further review

  • NNC0480-0389 was associated with significant reductions in HbA1c (-1.1 to -2.3; p<0.0001), body weight (-4.3% to -13%; p<0.0001), and stable total cholesterol levels 8.
  • Dietary interventions were associated with significant improvements in glycemic control as measured by blood sugar values (p<0.001) 12, while the DASH4D diet was associated with significant changes in systolic blood pressure (p<0.001) 13.
  • The FUSION closed-loop glucose control system showed 97.25% of glucose values within the target range of 70-180 mg/dL 17.
  • An initial insulin dosing calculator was associated with a significant reduction in clinical hyperglycemia (p=0.0005) 16.

For the clinician treating this condition

  • Semaglutide demonstrates consistent efficacy in weight reduction and improving patient treatment satisfaction while reducing insulin requirements.
  • Insulin Icodec is associated with significant HbA1c reduction, though clinical monitoring for hypoglycemia is noted.
  • NNC0480-0389 shows promise for concurrent management of HbA1c and body weight.
  • Non-pharmacological interventions including specific diets (DASH4D) and technology-based systems show measurable impacts on blood pressure and glycemic range maintenance.

AI synthesis of 10 cited trials, updated Jun 19, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Steviol glycosides serve as sucrose substitutes, but metabolic benefits need human validation
Nutrition & Obesity Medicine Sys. Review
Steviol glycosides serve as sucrose substitutes, but metabolic benefits need human validation Stevia Sweeteners May Help Reduce Sugar Intake for Healthier Foods
This narrative review examines stevia-derived sweeteners, specifically high-purity steviol glycosides, as sucrose substitutes. The authors r…
High-purity steviol glycosides can replace sugar in food products while maintaining taste, but more human studies are needed to confirm meta…
Frontiers Aug 7, 2026
AML infiltration of bile duct identified as primary cause of acute pancreatitis in case report
Rheumatology Sys. Review
AML infiltration of bile duct identified as primary cause of acute pancreatitis in case report Leukemia Cells Found as Cause of Severe Pancreatitis
This case report and literature review describes a 34-year-old man with acute pancreatitis and type 2 diabetes, where acute myeloid leukemia…
A rare case shows how a specific type of leukemia can infiltrate the pancreas and cause severe inflammation in patients with diabetes.
Frontiers Aug 3, 2026
Culturally tailored self-management interventions significantly decrease HbA1c levels in people with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Culturally tailored self-management interventions significantly decrease HbA1c levels in people with type 2 diabetes Culturally tailored programs help people with type 2 diabetes
This systematic review and meta-analysis of 7 studies found that culturally tailored self-management interventions lead to a significant red…
Tailoring diabetes management to a person's specific culture can lower blood sugar levels and improve daily habits like diet and exercise.
Aug 1, 2026
mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTs
Diabetes & Endocrinology Meta-analysis
mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTs Mobile Health Apps Help Manage Blood Sugar in Type 2 Diabetes
This meta-analysis of 19 RCTs with 2,166 participants found that mobile health (mHealth) app interventions significantly reduced HbA1c (MD -…
Using mobile health applications can help people with type 2 diabetes lower their blood sugar levels and improve their overall quality of li…
Frontiers Jul 30, 2026
SGLT2 inhibitors reduce body fat without significant impacts on skeletal muscle mass in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
SGLT2 inhibitors reduce body fat without significant impacts on skeletal muscle mass in type 2 diabetes SGLT2 Inhibitors Reduce Fat Mass in Type 2 Diabetes Patients
This network meta-analysis of 5,399 patients evaluated the effects of SGLT2 inhibitors on body composition. The study found that while SGLT2…
New analysis shows SGLT2 inhibitors consistently reduce body fat and weight in adults with type 2 diabetes without significantly reducing mu…
Frontiers Jul 29, 2026
Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation
Hematology Sys. Review
Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation Extracellular Vesicles Show Potential for Managing Metabolic Health Conditions
This systematic review evaluates the role of extracellular vesicles (EVs) in managing obesity, type 2 diabetes, MASLD, and atherosclerosis. …
New research identifies specific molecules within extracellular vesicles that may play a role in managing obesity, diabetes, and liver disea…
Frontiers Jul 29, 2026
Insulin resistance and hyperinsulinemia drive bidirectional links between biological aging and age-related chronic diseases
Diabetes & Endocrinology Sys. Review
Insulin resistance and hyperinsulinemia drive bidirectional links between biological aging and age-related chronic diseases Insulin Resistance Links Aging and Chronic Diseases
This narrative review explores the reciprocal relationship between insulin resistance, hyperinsulinemia, and mechanisms of biological aging.…
This review explores how insulin resistance and high insulin levels connect aging to diseases like diabetes, heart disease, and kidney disea…
Frontiers Jul 27, 2026
GLP-1 Receptor Agonists Associated with Reduced Cancer Risk in Patients with Type 2 Diabetes
Urology Meta-analysis
GLP-1 Receptor Agonists Associated with Reduced Cancer Risk in Patients with Type 2 Diabetes GLP-1 medications may lower cancer risk for people with diabetes
This meta-analysis investigated the impact of GLP-1 receptor agonists on overall and site-specific cancer risks in adults with Type 2 Diabet…
New analysis suggests that GLP-1 receptor agonists might reduce the risk of several types of cancer in adults with Type 2 Diabetes.
Frontiers Jul 24, 2026
Specific gut microbiota taxa are associated with the presence of diabetic retinopathy in T2DM patients
Ophthalmology Meta-analysis
Specific gut microbiota taxa are associated with the presence of diabetic retinopathy in T2DM patients Gut Bacteria Differences Linked to Diabetic Retinopathy in Diabetes Patients
This meta-analysis examined gut microbiota composition and diversity in individuals with Type 2 Diabetes Mellitus and Diabetic Retinopathy. …
Specific changes in gut bacteria are linked to diabetic retinopathy, a serious eye condition affecting people with Type 2 diabetes.
Jul 24, 2026
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
Cardiology Guideline
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Frontiers Jul 19, 2026
GQD plus metformin significantly reduces FPG and 2hPG in adults with Type 2 Diabetes
Diabetes & Endocrinology Meta-analysis
GQD plus metformin significantly reduces FPG and 2hPG in adults with Type 2 Diabetes Herbal remedy shows mixed results for type 2 diabetes
This meta-analysis of 725 patients evaluated the addition of Gegen Qinlian decoction to metformin for managing Type 2 Diabetes. While signif…
A Chinese herbal formula added to metformin lowered blood sugar after meals, but didn't improve long-term control. The evidence is very weak…
Frontiers Jul 17, 2026
Mediterranean and DASH diets consistently support mitigation of cardiometabolic risk in metabolic syndrome patients
Cardiology Sys. Review
Mediterranean and DASH diets consistently support mitigation of cardiometabolic risk in metabolic syndrome patients Mediterranean and DASH Diets Show Promise for Heart Health
This narrative review synthesizes evidence on dietary patterns for managing Metabolic Syndrome, Type 2 Diabetes Mellitus, and Chronic Kidney…
Specific eating patterns like the Mediterranean and DASH diets may help manage risks for heart disease and type 2 diabetes.
Frontiers Jul 15, 2026

Research across Type 2 Diabetes

Related studies from across the Type 2 Diabetes family.

Ecnoglutide improves glycemic control and reduces body weight in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Ecnoglutide improves glycemic control and reduces body weight in adults with type 2 diabetes Ecnoglutide Shows Promise for Type 2 Diabetes Management
This meta-analysis evaluated the efficacy of ecnoglutide in adults with type 2 diabetes compared to placebo and dulaglutide. The findings in…
Ecnoglutide may help manage blood sugar and reduce body weight in adults with type 2 diabetes, though more large-scale studies are needed.
Frontiers Sep 11, 2026
Short-bout accumulated physical activity reduces mean glucose in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Short-bout accumulated physical activity reduces mean glucose in adults with type 2 diabetes Short bursts of activity may lower blood sugar in diabetes
This meta-analysis of 175 participants indicates that short-bout accumulated physical activity and sedentary-break interventions reduce mean…
Short bursts of physical activity and frequent breaks from sitting may help lower average blood sugar levels for adults with type 2 diabetes…
Frontiers Sep 11, 2026
OSA Tied to Poorer Glucose Control in Type 2 Diabetes
Diabetes & Endocrinology Meta-analysis
OSA Tied to Poorer Glucose Control in Type 2 Diabetes Sleep Apnea Linked to Poorer Blood Sugar Control in Diabetes
Obstructive sleep apnoea is consistently linked to worse glucose control and insulin resistance in people with type 2 diabetes or prediabete…
People with Type 2 Diabetes and sleep apnea may face harder blood sugar management and higher insulin resistance.
Frontiers Sep 9, 2026
Survodutide Improves Beta Cell Function and Insulin Sensitivity in T2D and Obesity
Nutrition & Obesity Medicine RCT
Survodutide Improves Beta Cell Function and Insulin Sensitivity in T2D and Obesity Trial shows survodutide improves insulin sensitivity and beta-cell function
Survodutide demonstrates significant improvements in beta-cell function and insulin sensitivity across both T2D and overweight populations.
A new medication called survodutide may improve how the body handles insulin and supports the cells that produce it for people with type 2 d…
Sep 8, 2026
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes
Nutrition & Obesity Medicine Sys. Review
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes Trial shows different GLP-1 medications impact weight and blood sugar
A network meta-analysis evaluates GLP-1 receptor agonists in adolescents, identifying varying degrees of efficacy across weight, glucose, an…
New analysis of GLP-1 medications shows varying results for weight loss and blood sugar control in adolescents with obesity and type 2 diabe…
Sep 7, 2026
SGLT2 inhibitors not tied to gastrointestinal cancer risk in type 2 diabetes meta-analysis
Oncology Meta-analysis
SGLT2 inhibitors not tied to gastrointestinal cancer risk in type 2 diabetes meta-analysis SGLT2 inhibitors show no link to gastrointestinal cancer risk
This meta-analysis of 48,765 patients with type 2 diabetes found no significant association between SGLT2 inhibitor use and overall or site-…
New data suggests that SGLT2 inhibitors, a common treatment for type 2 diabetes, do not increase the risk of various gastrointestinal cancer…
Sep 6, 2026
CareAide mHealth application improves medication adherence and quality of life in type 2 diabetes
Diabetes & Endocrinology RCT
CareAide mHealth application improves medication adherence and quality of life in type 2 diabetes Pharmacist-led mobile app improves medication habits for type 2 diabetes
This multicentre randomized controlled trial of 663 patients with type 2 diabetes found that the CareAide mHealth application significantly …
A new mobile app led by pharmacists helps people with type 2 diabetes stay on track with their medications and improve their quality of life…
Sep 6, 2026
Exercise interventions improve metabolic flux and fatty acid oxidation in Type 2 Diabetes
Diabetes & Endocrinology Sys. Review
Exercise interventions improve metabolic flux and fatty acid oxidation in Type 2 Diabetes Exercise helps manage metabolic stress in Type 2 Diabetes
This narrative review explores how exercise interventions impact metabolic pathways in Type 2 Diabetes. The authors synthesize evidence that…
New research highlights how exercise helps clear harmful fats and balance metabolism for people living with Type 2 Diabetes.
Frontiers Sep 6, 2026
Evaluating Glycemic Control and Weight Reduction of SGLT2 Inhibitors Versus DPP-4 Inhibitors
Diabetes & Endocrinology Meta-analysis
Evaluating Glycemic Control and Weight Reduction of SGLT2 Inhibitors Versus DPP-4 Inhibitors High dose SGLT2 inhibitors show better blood sugar control
High-dose SGLT2 inhibitors demonstrate superior glycemic control and significant weight reduction compared to DPP-4 inhibitors in type 2 dia…
High-dose SGLT2 inhibitors may offer better blood sugar control and weight loss for people with type 2 diabetes compared to DPP-4 inhibitors…
Frontiers Sep 4, 2026
Higher Triglyceride-glucose index is associated with increased risk of diabetic peripheral neuropathy
Diabetes & Endocrinology Meta-analysis
Higher Triglyceride-glucose index is associated with increased risk of diabetic peripheral neuropathy High Triglyceride and Glucose Levels Linked to Nerve Damage in Diabetes
This meta-analysis of 32,281 patients with Type 2 Diabetes found that a higher TyG index is associated with an increased risk of diabetic pe…
High levels of fats and sugars in the blood can significantly increase the risk of nerve damage for people with type 2 diabetes.
Frontiers Sep 4, 2026
NT-proBNP and cTnI as Prognostic Biomarkers in Type 2 Diabetes Patients
Cardiology RCT
NT-proBNP and cTnI as Prognostic Biomarkers in Type 2 Diabetes Patients Heart health markers help predict risks for people with diabetes
NT-proBNP serves as a potent predictor of MACE and mortality in T2D patients, while cTnI may identify specific patient subgroups for exenati…
New data shows that specific heart markers can help predict serious heart events and help doctors understand how certain treatments work for…
Sep 3, 2026
GLP-1 receptor agonists reduce MACE (HR 0.69) and all-cause mortality (HR 0.67) in Type 2 Diabetes
Cardiology Meta-analysis
GLP-1 receptor agonists reduce MACE (HR 0.69) and all-cause mortality (HR 0.67) in Type 2 Diabetes GLP-1 medications show promise for heart health in diabetes
This meta-analysis of 37,393 patients with Type 2 Diabetes and myocardial infarction-defined populations found that GLP-1 receptor agonists …
A large review of over 37,000 patients suggests GLP-1 medications may lower heart failure risks for those with Type 2 Diabetes.
Sep 2, 2026

Questions about Type 2 Diabetes Mellitus

Does a higher nutritional risk index lower osteoporosis risk in women with Type 2 Diabetes?

Yes, a higher Geriatric Nutritional Risk Index (GNRI) is linked to lower osteoporosis risk in women with type 2 diabetes, based on multiple studies.

Full answer →
Which glucose-lowering therapies work best for heart failure and Type 2 Diabetes?

SGLT-2 inhibitors (like empagliflozin, dapagliflozin) are the most effective glucose-lowering therapies for heart failure in type 2 diabetes, reducing hospitalizations and cardiovascular death.

Full answer →